Top

Current Dermatology Reports

Published in:

01-12-2018 | IImmunology (D Lee, Section Editor)

Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities

Authors: Houmin Li, Delphine J. Lee

Published in: Current Dermatology Reports | Issue 4/2018

Abstract

Purpose of Review

While psoriasis has traditionally been considered primarily a skin and joint disorder, there is a new appreciation that psoriasis affects multiple organs. In fact, psoriasis is associated with several comorbidities that also affect the vasculature, guts, lung, kidney, and other tissues. This review aims to summarize the epidemiology and immunopathogenesis of psoriasis and its comorbidities.

Recent Findings

We reviewed the current literature characterizing the epidemiology and immune pathways of psoriasis and its comorbidities and report common inflammatory and immune pathways implicated in the pathogenesis of psoriasis and its comorbidities.

Summary

A variety of diseases are associated with psoriasis, including psoriatic arthritis, metabolic syndrome, atherosclerosis and cardiovascular disease, nonalcoholic fatty liver disease, inflammatory bowel disease, uveitis, and chronic obstructive pulmonary disease. These comorbidities share similar inflammatory and immune pathways with those that are classically implicated in psoriasis: especially the adipokines, TH17, and TNF-α.

Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16–7.PubMed

Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54(4):685–704.PubMed

Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.PubMed

Wu CY, Hu HY, Li CP, Chou YJ, Chang YT. Comorbidity profiles of psoriasis in Taiwan: a latent class analysis. PLoS One. 2018;13(2):e0192537.PubMedPubMedCentral

Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.PubMed

Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–3.PubMed

Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5):1037–43.PubMed

Chiu HY, Huang HL, Li CH, Yin YJ, Chen HA, Hsu ST, et al. Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: psoriasis comorbidities a nationwide population-based cohort study. Br J Dermatol. 2015;173(1):146–54.PubMed

Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142:1132–5.PubMed

10.

Buslau M, Benotmane K. Cardiovascular complications of psoriasis: does obstructive sleep apnoea play a role? Acta Derm Venereol. 1999;79(3):234.PubMed

11.

Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association? J Invest Dermatol. 2009;129(7):1643–9.PubMed

12.

Campolmi E, Zanieri F, Santosuosso U, D'Erme AM, Betti S, Lotti T, et al. The importance of stressful family events in psoriatic patients: a retrospective study. J Eur Acad Dermatol Venereol. 2012;26(10):1236–9.PubMed

13.

Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de Kerkhof PC, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247–55.PubMed

14.

Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28(3):554–9.PubMed

15.

Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin. 2004;22(4):477–86 x.PubMed

16.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.06.027.

17.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, et al. Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44(8):1151–8.PubMed

18.

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–62.PubMed

19.

Danielsen K, Wilsgaard T, Olsen AO, Eggen AE, Olsen K, Cassano PA, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol. 2015;172(2):419–27.PubMed

20.

Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT study, Norway. Br J Dermatol. 2018. https://doi.org/10.1111/bjd.16885.

21.

Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.PubMed

22.

Dowlatshahi EA, Kavousi M, Nijsten T, Ikram MA, Hofman A, Franco OH, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Invest Dermatol. 2013;133(10):2347–54.PubMed

23.

Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.PubMedPubMedCentral

24.

Alhomoud AS, Alnemer KA, Aldokheal MI, Alsultan AM, Alzahrani ZK. The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia. Electron Physician. 2017;9(11):5793–9.PubMedPubMedCentral

25.

Fang N, Jiang M, Fan Y. Association between psoriasis and subclinical atherosclerosis: a meta-analysis. Medicine (Baltimore). 2016;95(20):e3576.

26.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.PubMed

27.

Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25(4):383–91.PubMed

28.

Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics, and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778–86.PubMed

29.

Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53(3):190–7.PubMed

30.

Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–64.PubMed

31.

Awosika O, Eleryan MG, Rengifo-Pardo M, Doherty L, Martin LW, Ehrlich AA. Case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol. 2018;11(6):33–7.PubMedPubMedCentral

32.

Rinella M. Nonalcholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.PubMed

33.

Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckl). 2016;6:73–92.

34.

Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn’s disease. Gut. 1968;9(1):17–21.PubMedPubMedCentral

35.

Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genomewide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636–47.PubMedPubMedCentral

36.

Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5.PubMed

37.

Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–34.PubMed

38.

Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population based study. Gastroenterology. 2005;129(3):827–36.PubMed

39.

Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol. 1990;85(8):962–3.PubMed

40.

Li X, Kong L, Li F, Chen C, Xu R, Wang H, et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0145221.PubMedPubMedCentral

41.

Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e321–8.PubMed

42.

Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4):956–60.PubMed

43.

Chiang YY, Lin HW. Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2012;26(1):59–65.PubMed

44.

Erbagci I, Erbagci Z, Gungor K, Beckir N. Ocular anterior segment pathologies and tear film changes in patients with psoriasis vulgaris. Acta Med Okayama. 2003;57(6):299–303.PubMed

45.

Chandran NS, Greaves M, Gao F, Lim L, Cheng BC. Psoriasis and the eye: prevalence of eye disease in Singaporean Asian patients with psoriasis. J Dermatol. 2007;34(12):805–10.PubMed

46.

Fraga NA, Oliveira MF, Follador I, Rocha BO, Rêgo VR. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87(6):877–83.PubMedPubMedCentral

47.

Rehal B, Modjtahedi BS, Morse LS, Schwab IR, Maibach HI. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202–12.PubMed

48.

Chi CC, Tung TH, Wang J, Lin YS, Chen YF, Hsu TK, et al. Risk of uveitis among people with psoriasis: a nationwide cohort study. JAMA Ophthalmol. 2017;135(5):415.PubMedPubMedCentral

49.

Furue M, Kadono T. Psoriasis: behind the scenes. J Dermatol. 2016;43(1):4–8.PubMed

50.

Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–29.PubMed

51.

Ramírez-Valle F, Gray EE, Cyster JG. Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc Natl Acad Sci U S A. 2015;112(26):8046–51.PubMedPubMedCentral

52.

Ding C, Chan Z, Magkos F. Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype. Curr Opin Clin Nutr Metab Care. 2016;19(6):408–17.PubMed

53.

Rose S, Stansky E, Dagur PK, Samsel L, Weiner E, Jahanshad A, et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med. 2014;12:258.PubMedPubMedCentral

54.

Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.PubMedPubMedCentral

55.

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology. 2017;233(5):378–89.PubMed

56.

Aly DG, Abdallah IY, Hanafy NS, Elsaie ML, Hafiz NA. Elevated serum leptin levels in nonobese patients with psoriasis. J Drugs Dermatol. 2013;12(2):e25–9.PubMed

57.

Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, et al. Obesity, fat mass and immune system: role for leptin. Front Physiol. 2018;9:640.PubMedPubMedCentral

58.

Stelzner K, Herbert D, Popkova Y, Lorz A, Schiller J, Gericke M, et al. Free fatty acids sensitize dendritic cells to amplify Th1/Th17 cell-immune responses. Eur J Immunol. 2016;46(8):2043–53.PubMed

59.

McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34(12):2637–43.PubMedPubMedCentral

60.

Sumarac-Dumanovic M, Stevanovic D, Ljubic A, Jorga J, Simic M, Stamenkovic-Pejkovic D, et al. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes. 2009;33(1):151–6.

61.

Bertrand MJ, Tardif JC. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. Expert Opin Emerg Drugs. 2017;22(1):1–26.PubMed

62.

Robert M, Miossec P. Effects of interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017;16(9):984–91.PubMed

63.

Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, et al. IFN-γ and TNF-α synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. 2017;7(1):13831.PubMedPubMedCentral

64.

Youn SW, Kang SY, Kim SA, Park GY, Lee WW. Subclinical systemic and vascular inflammation detected by 18 F fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol. 2015;42(6):559–66.PubMed

65.

Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, et al. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy. J Dermatol. 2016;43(4):389–94.PubMed

66.

Kim DS, Shin D, Jee H, Kim TG, Kim SH, Kim DY, et al. Red blood cell distribution width is increased in patients with psoriasis vulgaris: a retrospective study on 261 patients. J Dermatol. 2015;42(6):567–71.PubMed

67.

Kim DS, Shin D, Lee MS, Kim HJ, Kim DY, Kim SM, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016;43(3):305–10.PubMed

68.

Pina T, Corrales A, Lopez-Mejias R, Armesto S, Gonzalez-Lopez MA, Gómez-Acebo I, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: a 6-month prospective study. J Dermatol. 2016;43(11):1267–72.PubMed

69.

Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: implications for immuno-pathophysiology of allergic inflammation. Eur J Immunol. 2007;37(8):2337–48.PubMed

70.

Suzukawa M, Nagase H, Ogahara I, Han K, Tashimo H, Shibui A, et al. Leptin enhances survival and induces migration, degranulation, and cytokine synthesis of human basophils. J Immunol. 2011;186(9):5254–60.PubMed

71.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.PubMed

72.

Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–73.PubMed

73.

Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61(5):1294–303.PubMedPubMedCentral

74.

Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol. 2011;166(2):281–90.PubMedPubMedCentral

75.

Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–74.PubMed

76.

Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143(3):765–76.PubMedPubMedCentral

77.

Zhang S, Huang D, Weng J, Huang Y, Liu S, Zhang Q, et al. Neutralization of interleukin-17 attenuates cholestatic liver fibrosis in mice. Scand J Immunol. 2016;83(2):102–8.PubMed

78.

Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, et al. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017;309(9):679–93.PubMedPubMedCentral

79.

Fiorino G, Omodei PD. Psoriasis and inflammatory bowel disease: two sides of the same coin? J Crohns Colitis. 2015;9(9):697–8.PubMed

80.

Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15(5):199–207.PubMed

81.

Thompson AI, Lees CW. Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17(3):831–48.PubMed

82.

Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.PubMedPubMedCentral

83.

Ehrlich D, Jamaluddin N, Pisegna J, Padua DA. Challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med. 2018;2018:9679287.PubMedPubMedCentral

84.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48.PubMed

85.

Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, et al. MEASURE 1 Study Group. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50–5.PubMed

86.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441–8.PubMed

87.

Ponce-Gallegos MA, Ramírez-Venegas A, Falfán-Valencia R. Th17 profile in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2017;12:1857–65.PubMedPubMedCentral

88.

Wei L, Laurence A, Elias KM, O’Shea JJ. IL-17s produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282(48):34605–10.PubMedPubMedCentral

89.

Matsuzaki G, Umemura M. Interleukin-17 family cytokines in protective immunity against infections: role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s. Microbiol Immunol. 2018;62(1):1–13.PubMed

90.

Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138(5):1140–7.PubMedPubMedCentral

91.

Pichavant M, Sharan R, Le Rouzic O, Olivier C, Hennegrave F, Rémy G, et al. IL-22 defect during Streptococcus pneumoniae infection triggers exacerbation of chronic obstructive pulmonary disease. EBioMedicine. 2015;2(11):1686–96.PubMedPubMedCentral

92.

Liang Y, Pan HF, Ye DQ. Tc17 cells in immunity and systemic autoimmunity. Int Rev Immunol. 2015;34(4):318–31.PubMed

93.

Xu WH, Hu XL, Liu XF, Bai P, Sun YC. Peripheral Tc17 and Tc17/interferon-γ cells are increased and associated with lung function in patients with chronic obstructive pulmonary disease. Chin Med J. 2016;129(8):909–16.PubMedPubMedCentral

94.

Yoshimura T, Sonoda KH, Miyazaki Y, Iwakura Y, Ishibashi T, Yoshimura A, et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol. 2008;20(2):209–14.PubMed

95.

Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711–8.PubMed

96.

Chen Y, Yang P, Li F, Kijlstra A. The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One. 2011;6(3):e18139.PubMedPubMedCentral

97.

Jawad S, Liu B, Agron E, Nussenblatt RB, Sen HN. Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm. 2013;21(6):434–9.PubMedPubMedCentral

98.

El-Asrar AM, Struyf S, Kangave D, Al-Obeidan SS, Opdenakker G, Geboes K, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139(2):177–84.PubMed

Title: Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities
Authors: Houmin Li
Delphine J. Lee
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Dermatology Reports / Issue 4/2018
Electronic ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0243-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epidemiology and Immunopathogenesis of Psoriasis and Its Comorbidities

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Healing Chronic Wounds: Current Challenges and Potential Solutions

Erythroderma and Figurate Erythemas

Patient Education in Atopic Dermatitis: Why It Is Needed and How to Improve It

Dress for Success: a Review of Dressings and Wound Care in Hidradenitis Suppurativa

Use of Lasers in Wound Healing: How to Best Utilize Laser Technology to Prevent Scar Formation

Advances in Immune Pathways and Pathogenesis of Atopic Dermatitis